JP2023541217A5 - - Google Patents

Info

Publication number
JP2023541217A5
JP2023541217A5 JP2023501419A JP2023501419A JP2023541217A5 JP 2023541217 A5 JP2023541217 A5 JP 2023541217A5 JP 2023501419 A JP2023501419 A JP 2023501419A JP 2023501419 A JP2023501419 A JP 2023501419A JP 2023541217 A5 JP2023541217 A5 JP 2023541217A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
sequence shown
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023501419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541217A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/105620 external-priority patent/WO2022007965A1/zh
Publication of JP2023541217A publication Critical patent/JP2023541217A/ja
Publication of JP2023541217A5 publication Critical patent/JP2023541217A5/ja
Priority to JP2026017958A priority Critical patent/JP2026071342A/ja
Ceased legal-status Critical Current

Links

JP2023501419A 2020-07-10 2021-07-09 抗IgE改変抗体及びその適用 Ceased JP2023541217A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026017958A JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010663029 2020-07-10
CN202010663029.3 2020-07-10
CN202110750959.7 2021-07-01
CN202110750959 2021-07-01
PCT/CN2021/105620 WO2022007965A1 (zh) 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026017958A Division JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Publications (2)

Publication Number Publication Date
JP2023541217A JP2023541217A (ja) 2023-09-29
JP2023541217A5 true JP2023541217A5 (cg-RX-API-DMAC7.html) 2024-07-17

Family

ID=79552269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023501419A Ceased JP2023541217A (ja) 2020-07-10 2021-07-09 抗IgE改変抗体及びその適用
JP2026017958A Pending JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026017958A Pending JP2026071342A (ja) 2020-07-10 2026-02-05 抗IgE改変抗体及びその適用

Country Status (11)

Country Link
US (1) US20230250191A1 (cg-RX-API-DMAC7.html)
EP (1) EP4180454A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023541217A (cg-RX-API-DMAC7.html)
KR (1) KR20230042030A (cg-RX-API-DMAC7.html)
CN (1) CN116018352A (cg-RX-API-DMAC7.html)
AU (1) AU2021306786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000400A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185192A1 (cg-RX-API-DMAC7.html)
IL (1) IL299747A (cg-RX-API-DMAC7.html)
TW (1) TWI896700B (cg-RX-API-DMAC7.html)
WO (1) WO2022007965A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318098A (en) 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
NZ601815A (en) * 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP4342541A3 (en) * 2017-04-07 2024-07-03 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
EP3788078A4 (en) * 2018-05-04 2022-03-02 Allakos Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA

Similar Documents

Publication Publication Date Title
JP2023075294A (ja) 抗cd47抗体及びその応用
CN109963588B (zh) 抗ctla4抗体
CN107922503B (zh) 一种pdl-1抗体、其药物组合物及其用途
CN112500485B (zh) 一种抗b7-h3抗体及其应用
JP7339948B2 (ja) モノクローナル抗体およびその使用法
TWI869334B (zh) 一種lag-3抗體醫藥組成物及其用途
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CA3082321A1 (en) Single domain antibodies that bind to cd137
CN110198739B (zh) 一种pd-l1抗体药物组合物及其用途
WO2022166802A1 (zh) 抗人cd271的单克隆抗体及用途
TWI914298B (zh) 特異性結合至人類T細胞受體之TRBV-9家族之β區的單株抗體及其使用之方法
CN112512550A (zh) 一种TGF-β受体融合蛋白药物组合物及其用途
CN105051067A (zh) 用于引起细胞内化的cd20结合免疫毒素及其使用方法
CN107955072A (zh) Pd-1抗体
BR122020002414B1 (pt) Uso de anticorpos anti-cd27 humanos
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
JP2026071342A5 (cg-RX-API-DMAC7.html)
TWI865727B (zh) 一種抗il-4r抗體醫藥組成物及其用途
JP2023535384A (ja) 抗pd-1抗体医薬組成物及びその用途
CN114981301A (zh) Pd1和vegfr2双结合剂
CN115715297A (zh) 抗flt3抗体和组合物
BR112021010948A2 (pt) Anticorpos agonistas de flt3 e seus usos
CN111956606A (zh) 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂
CN116018352A (zh) 一种抗IgE的工程化抗体及其应用
BR112021010414A2 (pt) Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas